What the FDA labels say about taking them together
Riociguat and sildenafil
Riociguat's FDA label of August 13, 2026 names sildenafil in its contraindications section, and sildenafil's label names riociguat too. The riociguat label: “Concomitant administration of Adempas with specific PDE-5 inhibitors or nonspecific PDE-5 inhibitors is contraindicated.”
Check it at the source: the riociguat FDA label on DailyMed (effective August 13, 2026, Bayer HealthCare Pharmaceuticals Inc.); the sildenafil FDA label on DailyMed (effective November 17, 2023, Viatris Specialty LLC).
What does the riociguat label say about sildenafil?
Riociguat label, contraindicationsConcomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )].
Riociguat label, drug interactionsPDE Inhibitors: Co-administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) and nonspecific PDE inhibitors (such as dipyridamole or theophylline), is contraindicated because of hypotension.
Source: FDA drug label (Adempas), Bayer HealthCare Pharmaceuticals Inc., effective August 13, 2026 (SPL set 7b57509a-3d5d-41d4-8fed-1471e26372a3), via openFDA; the full label on DailyMed
What does the sildenafil label say about riociguat?
Sildenafil label, contraindicationsAdministration with guanylate cyclase (GC) stimulators, such as riociguat
Revatio label (Viatris Specialty LLC, December 18, 2024), contraindicationsCONTRAINDICATIONS REVATIO is contraindicated in patients with: Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see Warnings and Precautions (5.1) ]. Concomitant use of riociguat, a guanylate cyclase stimulator.
Vybrique label (IBSA Pharma Inc., July 8, 2026), contraindicationsVYBRIQUE was shown to potentiate the hypotensive effect of nitrates. ( 4.1 , 7.1 , 12.2 ) Known hypersensitivity to sildenafil or any component of oral film. ( 4.2 ) Administration with guanylate cyclase (GC) stimulators, such as riociguat.
Source: FDA drug label (Revatio, NDA203109), Viatris Specialty LLC, effective December 18, 2024 (SPL set 3bb9363e-b28d-4019-8aae-539233dca214), via openFDA
Source: FDA drug label (Vybrique, NDA210858), IBSA Pharma Inc., effective July 8, 2026 (SPL set 9213fec1-e0c0-4ef7-9718-d97922a3f4d8), via openFDA
Source: FDA drug label (Viagra), Viatris Specialty LLC, effective November 17, 2023 (SPL set d905dc8d-917f-4ea3-a4ee-a1ecf6967d4e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Riociguat | Sildenafil | |
|---|---|---|
| Labeled for | Pulmonary arterial hypertension | Erectile dysfunction, Pulmonary arterial hypertension |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.132 per tablet 100 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once